UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|---|---|---|---|
| 10/723,144 | 11/25/2003 | Robert J. Ternansky | 474930-4<br>34433/US/3/AMP/S | 9257 |

20583 7590 06/24/2008

JONES DAY
222 EAST 41ST ST
NEW YORK, NY 10017

| EXAMINER | |
|---|---|
| CORDERO GARCIA, MARCELA M | |
| **ART UNIT** | **PAPER NUMBER** |
| 1654 | |
| **MAIL DATE** | **DELIVERY MODE** |
| 06/24/2008 | PAPER |

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

| APPLICATION NO./ CONTROL NO. | FILING DATE | FIRST NAMED INVENTOR / PATENT IN REEXAMINATION | ATTORNEY DOCKET NO. |
|---|---|---|---|
| 10723144 | 11/25/03 | TERNANSKY ET AL. | 474930-4 |

34433/US/3/AMP/S

JONES DAY
222 EAST 41ST ST
NEW YORK, NY 10017

| EXAMINER | |
|---|---|
| MARCELA M. CORDERO GARCIA | |
| **ART UNIT** | **PAPER** |
| 1654 | 20080617 |

**DATE MAILED:**

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

The reply filed on 6/11/08 is not fully responsive to the prior communication (5/19/08) because of the following omission(s) or matter(s): the CRF filed is not in compliance with 37 CFR 1.821-1.825. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR §§ 1.821- 1.825) in order to completely respond to this office action.

Specifically, the CRF dated 6/11/08 is flawed and has not been entered. Additionally, any amendments to the specification and drawing including SEQ ID NO:s need to be provided as amendments to the appropriate portions of the disclosure and to the drawings. In order to satisfy the sequence rules requirements, Applicant needs to provide an amendment to the instant claims, drawings and specification to include reference to the appropriate "SEQ ID NO:". In case of any new sequences not properly identified in the instant specification, Applicant is required to provide a substitute computer readable form (CRF) copy of a "Sequence Listing" which includes all of the sequences that are present in the instant application and encompassed by these rules, a new or substitute paper copy of that "Sequence Listing", an amendment directing the entry of that paper copy into the specification, and a statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. § 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d). The instant specification will also need to be amended so that it complies with 37 C.F.R. § 1.821(d) which requires a reference to a particular sequence identifier (SEQ ID NO:) be made in the specification and claims wherever a reference is made to that sequence. For rules interpretation Applicant may call (703) 308-1123. See M.P.E.P. 2422.04.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:
1. Electronically submitted through EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual - ePave)
2. US Postal Service:
Commissioner for Patents
PO Box 22313-1450
Alexandria, VA 22313-1450

3. Hand carry, Federal Express, United Parcel Service, or other delivery service:
U.S. Patent and Trademark Office
Mail Stop Sequence
Customer Window, Randolph Building
401 Dulany Street
Alexandria, VA 22314

/Marcela M Cordero Garcia/
Examiner, Art Unit 1654

```
============================================================
Sequence Listing could not be accepted.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).
Reviewer: Anne Corrigan
Timestamp: [year=2008; month=6; day=11; hr=16; min=52; sec=41; ms=214; ]
============================================================


************************************************************
Reviewer Comments:
<210> 7
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(methyl)

<400> 7
Pro His Ser Xaa
 1

The above <221> AMIDATION indicates location 5--there are only 4 amino
acids in this sequence.  Same type of error in Sequences 13-14, 32, 47-
49.

<210> 42
```

<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 8
<223> Xaa = Lys(biotin)

<400> 42
Pro Phe Ser Cys Asn Gly Gly Lys
 1               5

The above <220>-<223> section describing Xaa is incorrect: "Lys," not Xaa, is at location 8. Also, "<221> "AMIDATION" indicates location 5 instead of 8.
**********

**Validated By CRFValidator v 1.0.3**

Application No: 10723144 Version No: 1.0

**Input Set:**

**Output Set:**

**Started:** 2008-06-11 16:14:15.121
**Finished:** 2008-06-11 16:14:17.007
**Elapsed:** 0 hr(s) 0 min(s) 1 sec(s) 886 ms
**Total Warnings:** 50
**Total Errors:** 0
**No. of SeqIDs Defined:** 50
**Actual SeqID Count:** 50

| Error code | Error Description |
|---|---|
| W 213 | Artificial or Unknown found in <213> in SEQ ID (1) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (2) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (3) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (4) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (5) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (6) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (7) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (8) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (9) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (10) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (11) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (12) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (13) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (14) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (15) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (16) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (17) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (18) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (19) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (20) |

**Input Set:**

**Output Set:**

**Started:** 2008-06-11 16:14:15.121
**Finished:** 2008-06-11 16:14:17.007
**Elapsed:** 0 hr(s) 0 min(s) 1 sec(s) 886 ms
**Total Warnings:** 50
**Total Errors:** 0
**No. of SeqIDs Defined:** 50
**Actual SeqID Count:** 50

| Error code | Error Description |
|---|---|
| | This error has occured more than 20 times, will not be displayed |

SEQUENCE LISTING

<110> Ternansky, Robert J.
Allan, Amy L.
Donate, Fernando
Hopkins, Stephanie A.
Gladstone, Patricia L.
Mazar, Andrew
O'Hare, Sean M.
Parry, Graham
Plunkett, Marian
Yoon, Won Hyung

<120> PEPTIDES WHICH INHIBIT ANGIOGENESIS,CELL MIGRATION,
CELL INVASION AND CELL PROLIFERATION,COMPOSITIONS
AND USES THEREOF

<130> 9715-023-999

<140> 10723144
<141> 2008-06-11

<150> 60/429,174
<151> 2002-11-25

<150> 60/475,539
<151> 2003-06-02

<160> 50

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(beta,beta-dimethyl)

<400> 1
Pro His Ser Xaa Asn

1 5

<210> 2
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<400> 2
Pro His Ser Cys Asn
1 5

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(benzyl)

<400> 3
Pro His Ser Xaa Asn
1 5

<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(4-methyl-benzyl)

<400> 4
Pro His Ser Xaa Asn
 1               5


<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Met(O)

<400> 5
Pro His Ser Xaa Asn
 1               5


<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Met(O2)

<400> 6
Pro His Ser Xaa Asn
 1               5


<210> 7
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(methyl)

<400> 7
Pro His Ser Xaa
 1


<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(4-MeO-Phenyl)

<400> 8
Pro His Ser Xaa Asn
 1               5

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(parra-MeOBzl)

<400> 9
Pro His Ser Xaa Asn
 1               5


<210> 10
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(Ph)

<400> 10
Pro His Ser Xaa Asn
 1               5


<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(S-tBu)

<400> 11
Pro His Ser Xaa Asn
 1               5


<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(tBu)

<400> 12
Pro His Ser Xaa Asn
 1               5


<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>

<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 3
<223> Xaa = Cys(SMe)

<400> 13
His His Xaa Asn
 1


<210> 14
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 3
<223> Xaa = Cys(SMe)

<400> 14
His Ser Xaa Asn
 1


<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION

<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(SO2Bn)

<400> 15
Pro His Ser Xaa Asn
 1               5


<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = HoCys(SO2Ph)

<400> 16
Pro His Ser Xaa Asn
 1               5


<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4

<223> Xaa = HoCys(SOBn)

<400> 17
Pro His Ser Xaa Asn
 1               5


<210> 18
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(Bz)

<400> 18
Pro His Ser Xaa Asn
 1               5


<210> 19
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<400> 19
Pro His Ser Cys Asn
 1               5

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys((phenylthio)acetyl)

<400> 20
Pro His Ser Xaa Asn
 1               5


<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(Alloc)

<400> 21
Pro His Ser Xaa Asn
 1               5


<210> 22
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>

<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(Piv)

<400> 22
Pro His Ser Xaa Asn
 1               5


<210> 23
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(cyclohexanoyl)

<400> 23
Pro His Ser Xaa Asn
 1               5


<210> 24
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION

<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(nicotinoyl)

<400> 24
Pro His Ser Xaa Asn
 1               5


<210> 25
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(thiophene-2-carbonyl)

<400> 25
Pro His Ser Xaa Asn
 1               5


<210> 26
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4

<223> Xaa = Cys(allyl)

<400> 26
Pro His Ser Xaa Asn
 1               5


<210> 27
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(methoxyethane)

<400> 27
Pro His Ser Xaa Asn
 1               5


<210> 28
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(SMe)

<400> 28
Pro His Ser Xaa Asn
 1               5

<210> 29
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(SPh)

<400> 29
Pro His Ser Xaa Asn
 1               5


<210> 30
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(SCH2-(R)-CH(NH2)CO2H)

<400> 30
Pro His Ser Xaa Asn
 1               5


<210> 31
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = HoCys(Bz)

<400> 31
Pro His Ser Xaa Asn
 1               5


<210> 32
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 8
<223> Xaa = Lys(biotin)

<400> 32
Pro Phe Ser Cys Asn Gly Gly Lys
 1               5


<210> 33
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>

<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = HoCys(Piv)

<400> 33
Pro His Ser Xaa Asn
 1               5


<210> 34
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = HoCys(thiophene-2-carbonyl)

<400> 34
Pro His Ser Xaa Asn
 1               5


<210> 35
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION

<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = HoCys(methoxyethane)

<400> 35
Pro His Ser Xaa Asn
 1               5


<210> 36
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = HoCys(Bn)

<400> 36
Pro His Ser Xaa Asn
 1               5


<210> 37
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4

<223> Xaa = HoCys(SMe)

<400> 37
Pro His Ser Xaa Asn
 1               5


<210> 38
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = HoCys(SPh)

<400> 38
Pro His Ser Xaa Asn
 1               5


<210> 39
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Ala(beta-SO2Bn)

<400> 39
Pro His Ser Xaa Asn
 1               5

<210> 40
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = HoCys(Ph)

<400> 40
Pro His Ser Xaa Asn
 1               5

<210> 41
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<400> 41
Pro His Ser Ser Asn
 1               5


<210> 42
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>

<221> VARIANT
<222> 8
<223> Xaa = Lys(biotin)

<400> 42
Pro Phe Ser Cys Asn Gly Gly Lys
 1               5


<210> 43
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<400> 43
Pro Phe Ser Cys Asn
 1               5


<210> 44
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(Me)

<400> 44
Pro His Ser Xaa Asn
 1               5

<210> 45
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION

<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(acetyl)

<400> 45
Pro His Ser Xaa Asn
 1               5

<210> 46
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 4
<223> Xaa = Cys(acetamidomethyl)

<400> 46
Pro His Ser Xaa Asn
 1               5


<210> 47
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 3
<223> Xaa = Cys(Me)

<400> 47
Pro Ser Xaa Asn
 1


<210> 48
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<220>
<221> VARIANT
<222> 3
<223> X = Cys(ethyl)

<400> 48
Pro Ser Xaa Asn
 1


<210> 49
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<400> 49
Pro His Ser Ala
 1

<210> 50
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> synthesized peptide

<220>
<221> ACETYLATION
<222> 1

<220>
<221> AMIDATION
<222> 5

<400> 50
Pro His Ser Met Asn
 1               5

| Notice to Comply | Application No. 10/723,144 | Applicant(s) Ternansky et al. | |
|---|---|---|---|
| | Examiner M M Cordero Garcia | Art Unit 1654 | |

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☒ 7. Other: `Sequences missing from Sequence Listing.`

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951
For CRF Submission Help, call (571) 272-2510
PatentIn Software Program Support
Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845
PatentIn Software is Available At www.USPTO.gov

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY